Von Hippel-Lindau disease is an autosomal dominantly inherited disorder characterised by the development of haemangioblastomas, renal carcinomas, retinal angiomata, pancreatic tumours, and phaeochromocytomas . The tumour suppressor gene responsible for VHL has been mapped to 3p25 and a partial sequ
The von Hippel-Lindau gene : Turning discovery into therapy
β Scribed by Peter E. Clark; Michael S. Cookson
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 220 KB
- Volume
- 113
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The von Hippel-Lindau gene product (pVHL) interacts with and inhibits the cellular transcription factor elongin. However, the subcellular localization of pVHL has remained uncertain. Naturally occurring pVHL mutants which fail to interact with elongin have been described in patients with VHL disease
Communicated by Victor A. McKusick von Hippel-Lindau disease (VHL) is an inherited neoplastic disorder characterized by the development of tumors in the eyes, brain, spinal cord, inner ear, adrenal gland, pancreas, kidney, and epididymis. The VHL tumor suppressor gene was identified in 1993. Initial
## Abstract Deletions of the short arm of chromosome 3 are often observed in a specific subset of aggressive neuroblastomas (NBs) with loss of distal 11q and without __MYCN__ amplification. The critical deleted region encompasses the locus of the von HippelβLindau gene (__VHL__, 3p25). Constitution